Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for ...

Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...

Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...

Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...

Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure =3s, p = 0.012 DEE: 63.3% ...